As an extension of our previous work on the creation of cyclohepta[b]thiophene-containing compounds, the aim of this article is to create new lead compounds that include cyclohepta-thieno-oxazepine hybrids that could be applied as AChE and BChE inhibitors to treat AD [70,71,72]. Here, BCHE is linked to Alzheimer disease.